Paroxysmal hemicrania responding to topiramate.
Chronic paroxysmal hemicrania (CPH) is a rare primary headache syndrome, which is classified along with cluster headache and short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing (SUNCT) as a trigeminal autonomic cephalalgia. CPH is exquisitely responsive to indomethacin so much so that the response is one of the current diagnostic criteria. The case of a patient with CPH, who had marked epigastric symptoms with indomethacin treatment and responded well to topiramate 150 mg daily, is reported. Cessation of topiramate caused return of episodes, and the response has persisted for 2 years. Topiramate may be a treatment option in CPH.
Cohen
A S
AS
Headache Group, Institute of Neurology, The National Hospital for Neurology and Neurosurgery, Queen Square, London, UK.
Goadsby
P J
PJ
D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects / Q000627:therapeutic use; D000927:Anticonvulsants / Q000627:therapeutic use*; D005151:Facial Injuries / Q000150:complications; D005632:Fructose / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D007213:Indomethacin / Q000009:adverse effects / Q000627:therapeutic use; D008297:Male; D051302:Paroxysmal Hemicrania / Q000188:drug therapy* / Q000209:etiology; D000077236:Topiramate; D016896:Treatment Outcome
D000894:Anti-Inflammatory Agents, Non-Steroidal; D000927:Anticonvulsants; D000077236:Topiramate; D005632:Fructose; D007213:Indomethacin